Background: It is apparent that despite lack of family history, patients with the morphological characteristics of left ventricular non-compaction develop arrhythmias, thrombo-embolism and left ventricular dysfunction.
Ischemic stroke has been one of the major reason for morbidity and mortality all over the world. Anticoagulation treatment in patients with cerebral ischemic events caused by cardiac emboli is no longer a matter of debate. The problem is when to start. Because of a recurrence rate of 15 to 20% in the first few weeks after the initial event, direct anticoagulation by means of intravenous heparin followed by oral anticoagulants seems to be indicated. We are presenting 2 cases of patients who suffered cardio-embolic stroke due to cardiac thrombosis and had a therapeutic dilemma on when to start the anticoagulation treatment. Early anticoagulation treatment was associated with good clinical and neurological outcome. Keywords: anticoagulation; stroke; cardiac thrombus; cardio-embolic stroke; hemorrhagic stroke; warfarin.
One of the common questions for patients with a history of cardiovascular disease is whether it is safe for them to fast during Ramadan. Yet, studies on the effects of Ramadan fasting on blood lipids, blood pressure, anthropometric parameters and other cardiovascular risk factors are scarce, and have given inconclusive results. The aim of this study is to investigate the effect of Ramadan fasting on cardiovascular risk factors including biochemical indices, blood pressure and main anthropometric parameters. This Prospective observational study was conducted at the CCU (Coronary care unit) and medical wards of Madinat Zayed hospital one of Al Dhafra hospitals, under Seha Abu Dhabi. Fifty-Six diabetic patients admitted with cardiovascular events including 48 males and 8 females with a previous history of cardiovascular event completed the study. Their age ranged between 32 and 91 years with a mean of 54.0 ± 10 years. A non-significant slight biochemical modification with regard to the metabolic profile pre, during and post-Ramadan period was reported: eGFR, total cholesterol, LDL, and HDL were increased yet, triglycerides and creatinine were non-significantly lower during Ramadan. Findings also showed a non-significant decrease in the post Ramadan blood pressure values which could be attributed to the metabolic switch.
One of the common questions for patients with a history of cardiovascular disease is whether it is safe for them to fast during Ramadan. Yet, studies on the effects of Ramadan fasting on blood lipids, blood pressure, anthropometric parameters and other cardiovascular risk factors are scarce, and have given inconclusive results. The aim of this study is to investigate the effect of Ramadan fasting on cardiovascular risk factors including biochemical indices, blood pressure and main anthropometric parameters. This Prospective observational study was conducted at the CCU (Coronary care unit) and medical wards of Madinat Zayed hospital one of Al Dhafra hospitals, under Seha Abu Dhabi. Fifty-Six diabetic patients admitted with cardiovascular events including 48 males and 8 females with a previous history of cardiovascular event completed the study. Their age ranged between 32 and 91 years with a mean of 54.0 ± 10 years. A non-significant slight biochemical modification with regard to the metabolic profile pre, during and post-Ramadan period was reported: eGFR, total cholesterol, LDL, and HDL were increased yet, triglycerides and creatinine were non-significantly lower during Ramadan. Findings also showed a non-significant decrease in the post Ramadan blood pressure values which could be attributed to the metabolic switch.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.